About webadmin
This author has not written his bio yet.
But we are proud to say that webadmin contributed 635 entries already.
Entries by webadmin
ENA Poster (2022): A combination vertical inhibition approach with inhibitors of SHP2 and ERK provides improved activity in KRAS-mutant pancreatic and colorectal cancer models
/in 2022, ASTX029 - Solid Tumors, Products, UncategorisedView Poster: ENA Poster (2022): A combination vertical inhibition approach with inhibitors of SHP2 and ERK provides improved activity in KRAS-mutant pancreatic and colorectal cancer models
EORTC Poster (2022): Low SKP2 expression is predictive of sensitivity to an MDM2 antagonist in p53 wild-type AML
/in 2022, 2022, ASTX295 - Solid Tumors, Discovery, Posters, ProductsView Poster: Low Skp2 expression is predictive of sensitivity to an MDM2 antagonist in p53 wild-type AML
Third Success from Astex Drug Discovery Pharma Collaboration and Licence Agreements as AstraZeneca Receives US Marketing Approval for Cancer Drug Truqap (capivasertib)
/in 2023, NewsAstraZeneca’s TruqapTM (capivasertib) in combination with Faslodex® (fulvestrant) receives US FDA marketing approval for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more biomarker alterations (PIK3CA, AKT1 or PTEN). Astex is eligible to receive a milestone payment and royalties on sales of the new […]
Astex CSO David Rees Honoured as a Hero of Chemistry by the American Chemical Society
/in 2023, NewsCambridge, UK, 13 October 2023, Astex Pharmaceuticals (UK) (“Astex”), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system, congratulates its Chief Scientific Officer (CSO), David Rees PhD, FMedSci, FRSC on being honoured by the American Chemical Society (ACS) Heroes of Chemistry. […]
Astex Expands Drug Discovery Collaboration With MSD
/in 2023, News, UncategorisedCambridge, UK, 8 August 2023, Astex Pharmaceuticals (UK) (“Astex”), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system, today announced an exclusive worldwide research collaboration and license agreement with MSD (Merck & Co., Inc., Rahway, N.J., USA). The goal of the […]